High-risk patients and mRNA COVID vaccine response. Patients with B-cell malignancies and who have had chronic B-cell–depleting therapies have reduced response to mRNA COVID-19 vaccines. Strategies to protect these patients include rigorous public exposure avoidance, early intervention to try and reduce disease severity, minimizing exposure to chronic B-cell depletion, and third dose vaccine strategies.